R K D Pharmaceutical LLP is a globally focused pharmaceutical export and healthcare sourcing company providing access to high-quality pharmaceutical formulations, APIs, excipients, nutraceuticals, medical devices, surgical consumables, laboratory ins...
- (+91) 9004316713
- ajay.sharma@rkdpharmaceutical.com
- Unit no.414, 4th Floor, Marathon Max, Mulund – Goregaon Link road, Mulund West, , Mumbai, Maharashtra, India. 400080
© 2020 R K D PHARMACEUTICAL LLP. All Rights Reserved
Ceftriaxone 250 mg Injection
-
Product is not available
Country of origin : India
Active Strength & Injectable Presentation
Ceftriaxone 250 mg Injection is generally presented as a sterile powder containing ceftriaxone sodium equivalent to 250 mg of ceftriaxone in a single-dose vial. The powder requires reconstitution with an approved diluent before administration by a qualified healthcare professional. Hospital and institutional buyers should verify the pharmacopoeial standard, route of administration, batch certificate of analysis (COA), sterility documentation and destination-market authorization before procurement.
Composition & Physicochemical Properties
The vial contains ceftriaxone in the form of ceftriaxone sodium, typically supplied as a white to yellowish crystalline powder for solution for injection. Technical evaluation should cover identification, potency, related substances, water content, particulate matter, sterility, bacterial endotoxins and container-closure integrity against the approved specification. Compatible diluents, reconstitution instructions, solution stability and administration conditions must be confirmed from the manufacturer’s approved product information.
-
Additional Information
Clinical Application & Reconstitution Compatibility
This product is part of our Pharmaceutical Products range for hospitals, healthcare institutions, pharmaceutical distributors and tender-based procurement teams. Ceftriaxone is a cephalosporin antibacterial supplied in this presentation as sterile ceftriaxone sodium equivalent to 250 mg of ceftriaxone per vial. Depending on the authorized product information, the reconstituted preparation may be intended for intramuscular or intravenous administration. Buyers must verify the approved route, diluent, reconstitution procedure, packaging and labelling against destination-market requirements. Administration must be performed by qualified healthcare professionals according to the approved prescribing information.
- Country of Origin: Confirm from the manufacturer or supplier
- Regulatory/Pharmacopoeial Compliance: Confirm the applicable BP, Ph. Eur., USP or destination-market standard and product authorization from supporting documentation
- Quality Assurance / Shelf Life: Confirm sterility testing, batch release, approved storage conditions, post-reconstitution stability and labelled shelf life from manufacturer documentation
Manufacturing Compliance & Documentation
Request a Ceftriaxone 250 mg Injection Procurement Quote
Frequently Asked Questions
- What are the minimum order quantities and bulk options for Ceftriaxone 250 mg Injection? Minimum quantities depend on the manufacturer, vial and carton configuration, destination-market registration and tender requirements. Buyers should provide the required vial quantity and delivery schedule to confirm available options.
- How is pricing structured for institutional or large-volume purchases? Pricing may vary according to order volume, vial packaging, documentation requirements, destination and shipment terms. Share the required quantity, pack configuration and Incoterm to obtain an appropriate quotation.
- Are COA, sterility and regulatory documents available? Documentation availability must be confirmed before ordering. Buyers may request the batch COA, sterility and endotoxin results, finished-product specification, manufacturing authorization and market-registration documents.
- Are a diluent and reconstitution instructions supplied with the vial? Diluent inclusion and reconstitution requirements vary by manufacturer and market authorization. Confirm the supplied components, approved diluent, route of administration and reconstituted-solution stability from the product dossier before ordering.
-
Reviews ()
Write a Review
